Medtronic PLC $MDT Shares Sold by Olstein Capital Management L.P.

Olstein Capital Management L.P. lessened its holdings in Medtronic PLC (NYSE:MDT) by 16.1% during the 4th quarter, HoldingsChannel.com reports. The institutional investor owned 73,000 shares of the medical technology company’s stock after selling 14,000 shares during the quarter. Medtronic makes up approximately 1.4% of Olstein Capital Management L.P.’s holdings, making the stock its 23rd largest position. Olstein Capital Management L.P.’s holdings in Medtronic were worth $7,012,000 at the end of the most recent quarter.

A number of other hedge funds and other institutional investors also recently bought and sold shares of MDT. Barclays PLC boosted its position in shares of Medtronic by 104.6% during the 3rd quarter. Barclays PLC now owns 6,831,203 shares of the medical technology company’s stock worth $650,604,000 after acquiring an additional 3,492,192 shares in the last quarter. Schroder Investment Management Group raised its position in shares of Medtronic by 78.3% during the 3rd quarter. Schroder Investment Management Group now owns 7,529,849 shares of the medical technology company’s stock worth $717,143,000 after acquiring an additional 3,307,211 shares in the last quarter. Guinness Asset Management LTD acquired a new stake in shares of Medtronic during the 3rd quarter worth about $275,556,000. Wellington Management Group LLP lifted its stake in Medtronic by 35.3% during the third quarter. Wellington Management Group LLP now owns 10,189,586 shares of the medical technology company’s stock worth $970,456,000 after purchasing an additional 2,658,981 shares during the last quarter. Finally, SG Americas Securities LLC boosted its holdings in Medtronic by 2,297.7% in the fourth quarter. SG Americas Securities LLC now owns 2,510,712 shares of the medical technology company’s stock valued at $241,179,000 after purchasing an additional 2,406,000 shares in the last quarter. 82.06% of the stock is currently owned by institutional investors and hedge funds.

Insiders Place Their Bets

In related news, EVP Harry Skip Kiil sold 52,524 shares of the stock in a transaction on Thursday, February 19th. The shares were sold at an average price of $97.71, for a total transaction of $5,132,120.04. Following the completion of the sale, the executive vice president owned 32,768 shares in the company, valued at $3,201,761.28. This represents a 61.58% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at the SEC website. 0.26% of the stock is currently owned by corporate insiders.

Wall Street Analyst Weigh In

MDT has been the topic of several recent analyst reports. Robert W. Baird increased their price target on shares of Medtronic from $92.00 to $93.00 and gave the company a “neutral” rating in a research note on Wednesday, April 15th. Leerink Partners restated an “outperform” rating and set a $119.00 price objective on shares of Medtronic in a research report on Tuesday, March 10th. Argus lowered their target price on shares of Medtronic from $125.00 to $115.00 and set a “buy” rating for the company in a report on Monday, April 6th. CICC Research started coverage on shares of Medtronic in a research note on Friday, January 30th. They set an “outperform” rating on the stock. Finally, Weiss Ratings lowered shares of Medtronic from a “buy (b-)” rating to a “hold (c+)” rating in a research note on Tuesday, April 21st. Fifteen research analysts have rated the stock with a Buy rating and eleven have given a Hold rating to the stock. According to data from MarketBeat.com, the company presently has an average rating of “Moderate Buy” and an average price target of $107.80.

More Medtronic News

Here are the key news stories impacting Medtronic this week:

• Positive Sentiment: CE Mark for Stealth AXiS system — Medtronic announced CE Mark clearance for its Stealth AXiS platform (navigation, planning and robotics combined). This expands commercial opportunity in image‑guided surgery in Europe following earlier FDA approval and could accelerate adoption in spine/neurosurgery over the coming quarters. Following FDA Approval, Medtronic (MDT) Receives CE Mark For Stealth AXiS System
• Positive Sentiment: Adaptive DBS launch in India — Medtronic has launched its adaptive deep brain stimulation (aDBS) system for Parkinson’s in India, opening a large, fast‑growing market for neuromodulation and providing more real‑world data and revenue potential from emerging markets. Medtronic Expands Neuromodulation Reach With Adaptive DBS Launch In India
• Positive Sentiment: $20M investment in Orchestra BioMed — Medtronic funded a $20M tranche to Orchestra BioMed to support the BACKBEAT pivotal trial for AVIM therapy; the deal accelerates a partner’s trial execution and secures Medtronic optional exposure to a potential adjunct therapy that complements its pacemaker/CRM portfolio. Financially modest for MDT but strategically relevant. Orchestra BioMed Receives $20 Million Payment from Medtronic Under Previously Announced Financing Agreement
• Neutral Sentiment: Wall Street consensus remains broadly positive (average brokerage recommendation = Buy) but analysts’ views are mixed on valuation and near‑term upside; investor reaction will depend on whether guidance/earnings beats accelerate top‑line momentum. Is It Worth Investing in Medtronic (MDT) Based on Wall Street’s Bullish Views?
• Negative Sentiment: Shares pulled back amid market gains — coverage notes MDT shares recently fell while the broader market rose, reflecting short‑term profit taking, valuation pressure and technical weakness (trading below key moving averages). That short‑term selling can mute the impact of positive product/partnership news. Medtronic (MDT) Stock Sinks As Market Gains: Here’s Why

Medtronic Trading Up 0.5%

NYSE:MDT opened at $77.99 on Friday. The company has a market capitalization of $100.13 billion, a PE ratio of 21.72, a P/E/G ratio of 1.84 and a beta of 0.62. Medtronic PLC has a 52-week low of $77.16 and a 52-week high of $106.33. The stock’s 50 day moving average price is $87.26 and its 200 day moving average price is $94.43. The company has a quick ratio of 1.87, a current ratio of 2.54 and a debt-to-equity ratio of 0.57.

Medtronic (NYSE:MDT) last issued its quarterly earnings data on Tuesday, February 17th. The medical technology company reported $1.36 earnings per share for the quarter, beating analysts’ consensus estimates of $1.34 by $0.02. The company had revenue of $9.02 billion during the quarter, compared to analysts’ expectations of $8.89 billion. Medtronic had a return on equity of 14.82% and a net margin of 13.00%.The firm’s revenue for the quarter was up 5.8% on a year-over-year basis. During the same quarter in the previous year, the business earned $1.38 earnings per share. Medtronic has set its FY 2026 guidance at 5.620-5.660 EPS. On average, research analysts anticipate that Medtronic PLC will post 5.57 EPS for the current year.

Medtronic Announces Dividend

The firm also recently declared a quarterly dividend, which was paid on Friday, April 17th. Investors of record on Friday, March 27th were given a $0.71 dividend. The ex-dividend date was Friday, March 27th. This represents a $2.84 annualized dividend and a yield of 3.6%. Medtronic’s dividend payout ratio is 79.11%.

Medtronic Company Profile

Medtronic plc is a global medical technology company that develops and manufactures a broad range of therapeutic devices and health care solutions. Headquartered legally in Ireland with principal operational offices in the United States, the company markets products to hospitals, physicians and health systems worldwide and has grown from its founding in 1949 into one of the largest medical-device manufacturers serving global health-care markets.

Medtronic’s offerings span several clinical areas, including cardiac rhythm and heart failure (pacemakers, implantable cardioverter‑defibrillators and related cardiac therapies), minimally invasive and surgical technologies (laparoscopic and advanced energy devices, visualization systems and surgical innovations), restorative therapies (spine and orthopedics, neuromodulation and neurovascular treatments) and diabetes management (insulin-delivery systems and glucose monitoring solutions).